Vimta Labs Limited — Important, 06-06-2025: General Updates

Vimta Labs has announced a board meeting to approve the financial results for the quarter and half-year. Shareholders approved expanding into CDMO activities across drug discovery, biotech, pharmaceuticals, biopharma, and related sectors, along with increased focus on R&D in biologics, biosimilars, peptides, and complex generics. Remuneration for the MD and two Executive Directors was also revised. This strategic shift aims to strengthen Vimta’s footprint in high-growth biotech and pharma service segments.